Brigatinib Regulatory Status in NSCLC

Video

Transcript: Ross Camidge, MD, PhD: ALTA-1L met every one of its primary end points, so it’s clearly going to be approved in the first-line setting.

Lyudmila A. Bazhenova, MD: Our phase II ALTA trial, which was a second-line trial in patients who progressed on crizotinib, was updated at ASCO [the American Society of Clinical Oncology] 2018 annual meeting. In that trial, median progression-free survival on brigatinib was slightly over 16 months, which is also quite consistent with ALTA-1L trial. Remember, in the ALTA-1L trial, patients who were randomized to crizotinib were then allowed to cross over to brigatinib. In patients who crossed over to brigatinib, median progression-free survival was about 15 months. So we now have 2 different clinical trials using brigatinib in second line, which show very similar progression-free survival of about 15 to 16 months.

Transcript Edited for Clarity

Related Videos
Arya Amini, MD
Vlad Gabriel Zaha, MD, PhD
Raj Singh, MD
Bruna Pellini, MD
Benjamin Levy, MD
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Jobelle Baldonado, MD
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Chul Kim, MD, MPH
Salman R. Punekar, MD, Mayo Clinic